Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Evaluation of the NJSPB SCF Project for Opioid-Involved High-Risk Parolees

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03812484
Recruitment Status : Enrolling by invitation
First Posted : January 23, 2019
Last Update Posted : March 13, 2019
Sponsor:
Information provided by (Responsible Party):
Clarissa Manning, Botec Analysis, LLC

Brief Summary:
This study entails an evaluation of the New Jersey State Parole Board Swift, Certain, and Fair (SCF) Supervision Program. The purpose of the evaluation is to test whether subjects assigned to SCF Supervision perform better than those assigned to parole-as-usual (PAU).

Condition or disease Intervention/treatment Phase
Substance Abuse Criminal Behavior Behavioral: SCF Supervision Behavioral: Parole-as-Usual Not Applicable

Detailed Description:
The Swift, Certain, and Fair (SCF) Supervision Program - Including Project HOPE Program provides funding to states, units of local government, territories, and federally recognized Indian tribes (as determined by the Secretary of the Interior) in an effort to enhance public safety, foster collaboration, and to improve the outcomes of individuals under the supervision of community corrections. The goals of this program are to develop and enhance SCF initiatives and implement the SCF model with fidelity, resulting in reduced recidivism and better outcomes for program participants. SCF approaches are intended to: (a) improve supervision strategies that reduce recidivism; (b) promote and increase collaboration among agencies and officials who work in community corrections and related fields to enhance swift and certain sanctions; (c) enhance the offenders' perception that the supervision decisions are fair, consistently applied, and consequences are transparent; and (d) improve the outcomes of individuals participating in these initiatives. The grantee will use awarded grant funds to support programming that provides services to up to 75 opioid involved parolees with services to divert them from a return to prison and manage underlying addictions with a combination of behavioral therapy and medication assisted treatments. The program combines sanctions with targeted reentry and treatment services.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Evaluation of the New Jersey State Parole Board Swift, Certain, and Fair Project for Opioid-Involved High-Risk Parolees
Actual Study Start Date : February 1, 2019
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 18, 2020

Arm Intervention/treatment
Experimental: SCF Parole
Parolee supervised under the SCF Supervision model
Behavioral: SCF Supervision
SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.

Active Comparator: Parole-As-Usual
Parolees are supervised under standard parole supervision practice in New Jersey.
Behavioral: Parole-as-Usual
Parolees are supervised under standard parole supervision practice in New Jersey
Other Name: PAU




Primary Outcome Measures :
  1. Revocation Rate [ Time Frame: 12 months ]
    Percentage of subjects in each condition who are revoked from parole and returned to prison


Secondary Outcome Measures :
  1. Days Incarcerated [ Time Frame: 12 months ]
    Total number of days incarcerated in jail or prison

  2. New Charges [ Time Frame: 12 months ]
    Number of new charges

  3. Percent Positive Drug Tests [ Time Frame: 12 months ]
    Percentage of random and scheduled drug tests that test positive for illicit drugs



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants must be 18 years of age or older
  • Participants must have a history of opioid use or addiction
  • Participants have a history of parole violations or active parolees who are at risk for violation (this can include anyone who is reentering the active population from prison)
  • Participants reside in or are moving to Ocean County; and
  • Participants must have at least 6 months remaining on their Parole term

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03812484


Locations
Layout table for location information
United States, New Jersey
New Jersey Reentry Corporation
Toms River, New Jersey, United States, 08753
Sponsors and Collaborators
Botec Analysis, LLC
Investigators
Layout table for investigator information
Principal Investigator: Clarissa Manning, MPP Botec Analysis, LLC

Layout table for additonal information
Responsible Party: Clarissa Manning, Director of Business Operations, Botec Analysis, LLC
ClinicalTrials.gov Identifier: NCT03812484     History of Changes
Other Study ID Numbers: CC100
First Posted: January 23, 2019    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders